|
Bavituximab (PGN401) is a chimeric monoclonal antibody designed for the treatment of cancers and viral infections.〔(Bavituximab (USAN/INN) )〕 It was developed by UT Southwestern Medical Center and Philip E. Thorpe and is currently owned by Peregrine Pharmaceuticals, Inc.〔http://www.peregrineinc.com/about-us/philip-thorpe-ps-targeting-antibody-inventor.html〕 ==Mechanism of action== Bavituximab binds to phosphatidylserine which is exposed on the surface of certain atypical animal cells, including tumour cells and cells infected with any of six different families of virus. These viral families contain the viruses hepatitis C, influenza A and B, HIV 1 and 2, measles, respiratory syncytial virus, pichinde virus, which is a model for the Lassa virus,〔Nature Medicine 14, 1357 - 1362 (2008)〕 and Ebola virus〔http://downloads.hindawi.com/journals/jir/aip/347903.pdf〕 Other cells are not affected since phosphatidylserine normally is only intracellular. Bavituximab binds to various aminophospholipids and is dependent on interaction with plasma protein beta-2 glycoprotein I to mediate binding. These target aminophospholipids, usually residing only on the inner leaflet of the plasma membrane of cells, become exposed in virally infected, damaged or malignant cells, and more generally in most cells undergoing the process of apoptosis. The antibody's binding to phospholipids alerts the body’s immune system to attack the tumor endothelial cells, thrombosing the tumor's vascular network and/or attacking free floating virally infected and metastatic cells while potentially minimizing side effects in healthy tissues. Data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) journal, Cancer Immunology Research. Bavituximab is currently being evaluated in several solid tumor indications.〔http://www.peregrineinc.com/pipeline/bavituximab-oncology.html〕〔http://cancerimmunolres.aacrjournals.org/content/1/4/256.abstract〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「bavituximab」の詳細全文を読む スポンサード リンク
|